Status:
COMPLETED
A Study in People With Mild Hypertension
Lead Sponsor:
Eli Lilly and Company
Conditions:
Mild Hypertension
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The primary objective of this study is to test the hypothesis that LY518674, administered for 6 weeks to patients with mild hypertension, reduces Systolic Blood Pressure, compared with placebo.
Eligibility Criteria
Inclusion
- Are men and women between 18 and 70 years of age, inclusive
- Have given signed informed consent to participate in this study
- Are diagnosed with mild essential hypertension at screening (currently untreated or treated with monotherapy)
Exclusion
- Secondary or malignant hypertension
- Have or have had a history of hyperlipidemia within 3 months of screening requiring treatment
- Any previous cardiovascular disease other than hypertension
- Type 1 or 2 diabetes
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
End Date :
November 1 2006
Estimated Enrollment :
153 Patients enrolled
Trial Details
Trial ID
NCT00374855
Start Date
September 1 2006
End Date
November 1 2006
Last Update
May 15 2007
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test
Åmål, Sweden, SE66230
2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test
Falköping, Sweden, 52143
3
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test
Gothenburg, Sweden, SE 41137
4
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test
Järfälla, Sweden, 17731